Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vixotrigine
- Development stage
- Phase 3
- Lead developer
- Biogen
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Vixotrigine (also known as BIIB074 or CNV1014802) is an orally bioavailable, small molecule state-dependent sodium channel blocker that preferentially inhibits the voltage-gated sodium channel Nav 1.7 (SCN9A). Developed by Biogen following its 2015 acquisition of Convergence Pharmaceuticals, the drug is designed to treat various neuropathic pain conditions by selectively blocking sodium channels in a use-dependent manner. This mechanism is intended to provide potent analgesic effects while minimizing the central nervous system side effects and dose-titration requirements associated with non-selective sodium channel blockers like carbamazepine. Vixotrigine has been investigated in clinical trials for trigeminal neuralgia, lumbosacral radiculopathy (sciatica), and small fiber neuropathy, though several late-stage programs were discontinued following mixed clinical results.
- Brand names
- vixotrigine
- Other names
- vixotrigine
02
Targets
NaV (Voltage-gated sodium channels)MAOB (Monoamine oxidase B)
Beyond the preview
Go deeper on vixotrigine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vixotrigine.